Log In
Print
BCIQ
Print
Print this Print this
 

Ibodutant (MEN 15596)

  Manage Alerts
Collapse Summary General Information
Company Menarini Group
DescriptionNon-peptide, selective antagonist of the tachykinin neurokinin 2 (NK2) receptor (TACR2)
Molecular Target Neurokinin 2 (NK2) receptor (TACR2)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationIrritable bowel syndrome
Indication DetailsTreat irritable bowel syndrome (IBS); Treat irritable bowel syndrome with diarrhea (IBS-D)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today